The Lancet Oncology in conversation with

The Lancet Group
  • 5.0 (1)
  • MEDICINE
  • UPDATED BIMONTHLY

Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.  A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.

  1. FEB 2

    Dylan Graetz and Erica Kaye on qualitative research in oncology

    Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Dylan Graetz (Department of Oncology and Department of Global Pediatric Medicine, St Jude Children’s Research Hospital) and Dr Erica Kaye (Department of Oncology, St Jude Children’s Research Hospital) to discuss qualitative in oncology. Read the full Reviews: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00669-2 for The Power of Words: Evaluating the Role of Qualitative Methods in Cancer Research and https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00670-9 for Expert Recommendations for the Conduct and Appraisal of Qualitative Research in Oncology and the reviews in  Lancet Haematology 2026  https://doi.org/10.1016/S2352-3026(25)00321-7 and eClinicalMedicine https://doi.org/10.1016/j.eclinm.2025.103736 Tell us what you thought about this episode Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.  You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    43 min

  2. 12/29/2025

    Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers

    Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak (Division of Cancer Prevention and Control, The Ohio State University) and Dr Marissa Baker (Department of Environmental & Occupational Health Science, University of Washington School of Public Health) to discuss their population-based study analysing cancer mortality rates by sex, cancer type, and occupation type among working-age adults in the USA. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00593-5/fulltext Tell us what you thought about this episode Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.  You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    24 min

  3. 11/25/2025

    Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3

    Dr Andre Pfob (Department of Obstetrics & Gynecology, Heidelberg University Hospital) and Prof Peter Dubsky (Faculty of Health Sciences and Medicine, University of Lucerne) discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus. Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00463-2/fulltext Tell us what you thought about this episode Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.  You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    27 min

  4. 11/02/2025

    Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission

    Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care. Click here to read the full Commission: The human crisis in cancer: a Lancet Oncology Commission And comment: Re-establishing human-centred care Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    11 min

  5. 10/27/2025

    Matthias Preusser on the phase 2 TUXEDO-3 trial

    Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer.  Hear about the potential of HER3-targeted antibody-drug conjugates for brain metastases, why recruiting patients with active brain metastases to clinical trials is so important, and where the field is going next. Click here to read the full article: Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial Click here to read the full article: Patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    17 min

  6. 09/29/2025

    Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer

    Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue. Effective treatments are needed for patients with muscle-invasive bladder cancer scheduled for radical cystectomy who are ineligible for or decline to receive neoadjuvant cisplatin-based chemotherapy. SunRISe-4 is a randomised, open-label, phase 2 trial being conducted at 109 investigative centres in ten countries worldwide, and aims to evaluate the safety and efficacy of neoadjuvant TAR-200 plus cetrelimab (anti-PD-1) versus cetrelimab monotherapy in this disease setting. They discuss the unique features of the TAR-200 localised sustained delivery system for gemcitabine, the key findings from the SunRISe4-trial trial, and what the future implications of the findings are in terms of better treatment options for patients with bladder cancer. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00358-4/abstract?dgcid=buzzsprout_icw_podcast_September_25_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    12 min

  7. 09/02/2025

    Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas

    Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expression and TERT promoter mutations in meningiomas. In these two cohort studies, the authors analyse the expression of TERT and TERT promoter mutations in meningiomas, assess their association with patient outcomes, and discuss the potential implications for patient management and the classification of these tumours. You can read the two Articles here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00267-0/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanonc https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00422-X/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    14 min

  8. 07/28/2025

    Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer

    Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Dr Jinming Li, from the Department of Colorectal Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China to discuss his international, multicohort, observational study on patterns in genomic mutations among patients with early-onset colorectal cancer. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00239-6?dgcid=buzzsprout_icw_podcast_July_25_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    8 min
See All (72)

About

Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.  A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.

Information

More From The Lancet Group

You Might Also Like